At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Neurovascular Dysfunction and Oxidative Stress in the Exercise Intolerance of Renal Failure
In Brief
A Phase 2 clinical trial evaluating Tetrahydrobiopterin, Placebo, and 1 other intervention for Kidney Failure, Chronic. Completed, enrolled 74 participants across 2 sites.
Detailed Summary
Patients with chronic kidney disease have profound exercise intolerance which contributes to an increased risk of cardiovascular disease. The investigators have found that chronic kidney disease patients have an exaggerated increase in blood pressure during certain forms of exercise that could certainly contribute to exercise dysfunction as well as cardiovascular risk. The investigators will test the mechanisms underlying this exaggerated blood pressure response, as well as the potential benefits of short-term tetrahydrobiopterin (BH4) with folic acid on both exercise dysfunction and cardiovascular risk factors in chronic kidney disease. The investigators will test whether short-term treatment with tetrahydrobiopterin (BH4), a cofactor for nitric oxide, together with folic acid improves inflammation, vascular health, and adrenaline levels, both at rest and during exercise in chronic kidney disease.
Study Details
Timeline
Interventions
Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
2 placebo pills PO BID for12 weeks
Folate 1 mg daily for 12 weeks